Evidence map›Paper›PMID 38464203›Full record

ArticleResearch square2024

Hu8F4-CAR T cells with mutated Fc spacer segment improve target-specificity and mediate anti-leukemia activity

Jeffrey Molldrem, Hong He, Rolando Vedia, Sijie Lu, Qiaochuan Li, Kathryn Cox, Lisa St John, Anna Sergeeva, Karen Clise-Dwyer, Gheath Alatrash and 2 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Jeffrey MolldremThe University of Texas MD Anderson Cancer Center.ORCID 0000-0003-1196-1715
Hong HeThe University of Texas MD Anderson Cancer Center.
Rolando VediaThe University of Texas MD Anderson Cancer Center.ORCID 0000-0001-8510-8608
Sijie LuMD Anderson.
Qiaochuan LiThe University of Texas MD Anderson Cancer Center.
Kathryn CoxThe University of Texas MD Anderson Cancer Center.
Lisa St JohnThe University of Texas MD Anderson Cancer Center.
Anna SergeevaThe University of Texas MD Anderson Cancer Center.
Karen Clise-DwyerUniversity of Texas MD Anderson Cancer Center.
Gheath AlatrashThe University of Texas MD Anderson Cancer Center.
Elizabeth ShpallThe University of Texas MD Anderson Cancer Center.
Qing MaThe University of Texas MD Anderson Cancer Center.
The University of Texas MD Anderson Cancer Center · USAnderson University - South Carolina · US

Funding

University of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KONOPLEVA, MARINA Y · 2003 to 2023
$43.7M
NCI NIH HHS P50 CA100632
6 · The paper itself

Abstract

Hu8F4 is a T cell receptor (TCR)-like antibody with high affinity for leukemia-associated antigen PR1/HLA-A2 epitope. Adapted into a chimeric antigen receptor (CAR) format, Hu8F4-CAR is comprised of the Hu8F4 scFv, the human IgG1 CH2CH3 extracellular spacer domain, a human CD28 costimulatory domain, and the human CD3ζ signaling domain. We have demonstrated high efficacy of Hu8F4-CAR-T cells against PR1/HLA-A2-expressing cell lines and leukemic blasts from AML patients

Indexed as

AMLCAR-T cellHu8F4PR1

Identifiers

PMID38464203
PMCPMC10925463
OpenAlexW4391925210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.